trending Market Intelligence /marketintelligence/en/news-insights/trending/PcM5tUd-lfDNvwrlL1ylBA2 content esgSubNav
In This List

Clinigen regains exclusive rights to commercialize 2 cancer therapies

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Clinigen regains exclusive rights to commercialize 2 cancer therapies

Cumberland Pharmaceuticals Inc. said it returned the U.S. commercial rights to two cancer drugs, Ethyol and Totect, to Clinigen Group PLC.

Nashville, Tenn.-based Cumberland signed agreements with Clinigen to acquire the exclusive U.S. rights to commercialize Ethyol and Totect in 2016 and 2017, respectively.

Ethyol, or amifostine, is indicated to treat dry mouth in patients undergoing post-operative radiation treatment for head and neck cancer, and to reduce the negative side effects of chemotherapy in patients with advanced ovarian cancer.

Totect, or dexrazoxane, is used for treating any accidental liquid leakage into the surrounding tissue due to chemotherapy.

After a review of its product portfolio, Cumberland decided in May to return the commercial rights of the two products to Clinigen and terminate the agreements, effective Sept. 30.

The companies amended the agreement in September, changing the transition date to Dec. 31, after which Cumberland will stop distributing the drugs and receive $5 million over a two-year period.